Hikma Pharmaceuticals (HIK)
15/01/2018 - 09:39 StockMarketWire
Hikma Pharmaceuticals has appointed Surendera Tyagi as group chief scientific officer and global head of research and d...
15/01/2018 - 08:00 RNS
RNS Number: 8062B Hikma Pharmaceuticals Plc 15 January 2018 PRESS RELEASE Hikma Appoints Dr. Surendera Tyagi as Group Chief Scientific Officer and Global Head of R&D London, 15 January 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), today announc...
10/01/2018 - 12:20 StockMarketWire
Jefferies International today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to underperfor...
04/01/2018 - 11:19 RNS
RNS Number: 9826A Hikma Pharmaceuticals Plc 04 January 2018 Hikma Pharmaceuticals PLC Total Voting Rights and Capital LONDON, 4 January 2018 - In accordance with the UK Financial Conduct Authority's (the " FCA ") DTR 5.6.1, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 31 D...
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment